Finally, we assessed therapeutic potential of TOP1 inhibitor for targeting WRN‐deficient melanoma tumor, which otherwise is known to be resistant to other therapeutic modalities (Figure 6d,e) (Gupta et al., 2021). Here, WRN is linked to melanoma.